Scribe Therapeutics retweeted
Great to welcome scientists from Amgen, Grifols, and Scribe Therapeutics to the @UCBerkeley MCB Industrial Affiliates Program symposium. Industry partners met with MCB grad students & postdocs, building bridges between academia and biotech innovation.
Scribe Therapeutics retweeted
Beyond Statins
Strokes and Heart Attacks Kill. New Drugs Are Coming to Prevent Them. barrons.com/articles/strokes…
Scribe Therapeutics retweeted
Benjamin Oakes, Ph.D., Scribe Therapeutics cofounder and CEO, spoke about what the next generation of therapies looks like at the 2024 Forbes Healthcare Summit in New York City. #ForbesHealth trib.al/BnATMd9
Scribe Therapeutics retweeted
"Our goal at Scribe is ultimately to create genetic medicines that are safe and effective enough for all."
Benjamin Oakes, Ph.D., Scribe Therapeutics cofounder and CEO, spoke at the 2024 Forbes Healthcare Summit in New York City. #ForbesHealth forbes.com/connect/event/202…
Scribe Therapeutics retweeted
Excited to join @TheAlexKnapp at the @Forbes Healthcare Summit! Can’t wait to explore @scribetx’s latest breakthroughs in #CRISPR gene editing and epigenetic silencing. The future of medicine is closer—and brighter—than ever! 🧬 #GeneEditing
Scribe Therapeutics retweeted
@BenjaminLOakes, CEO of @scribetx, discusses the application of engineering to biology with a16z Bio+Health general partner, @vijaypande, on Raising Health.
The two emphasize the potential of genetic medicine to not only treat but prevent diseases, leveraging CRISPR technology's advancements for safer and more effective therapeutic approaches.
Listen to the full conversation: a16z.com/podcast/crispr-by-d…
Scribe Therapeutics retweeted
From the bench to the forefront of health, CRISPR is not just editing genes—it's forcing us to rewrite the rules of medicine.
@BenjaminLOakes joined me on @a16z Raising Health to share his journey from the @doudna_lab to founding CEO of @scribetx, and how he’s focused on making CRISPR more precise & safe. @a16zBioHealth
bio-eats-world.simplecast.co…
Scribe Therapeutics retweeted
"We've chosen to apply engineering [to the problem] because if you start with Cas9, not only are you kind of weighed down by all of the baggage that that molecule has, you also are weighed down by the additional challenge of using it within the broader context of the field." - @BenjaminLOakes, Cofounder and CEO of @scribetx on the CRISPR by Design platform.
Recently, Ben joined a16z Bio+Health founding general partner @vijaypande on Raising Health where they talked about Ben's early career, experiences in the Doudna lab, the reasons behind co-founding Scribe, and the latest developments in CRISPR technology.
Listen to the full conversation: bio-eats-world.simplecast.co…
Scribe Therapeutics retweeted
Meet the Business Times' new class of Most Influential Women in Bay Area Business. bizjournals.com/sanfrancisco…
Scribe Therapeutics retweeted
Sanofi, Scribe to develop genetic medicines for sickle cell disease
firstwordpharma.com/story/57…
$SNY @scribetx
Scribe Therapeutics retweeted
Continuing the streak of exciting news! 🚀Less than a year into our partnership with @sanofi, we're ushering in the next phase of collaboration. Our aim? To develop a revolutionary treatment that could potentially treat SCD at scale.🌍
Read the PR: businesswire.com/news/home/2…
1/ We’re thrilled to announce the expansion of our collaboration with @sanofi, leveraging Scribe’s proprietary #CRISPR X-Editing (XE) technologies to drive a new wave of in vivo therapies for genomic diseases, beginning with #SickleCell disease.
businesswire.com/news/home/2…
Scribe Therapeutics retweeted
Sanofi expands research deal with gene editing startup Scribe biopharmadive.com/news/scrib… $SNY by @gwendolynawu
Scribe Therapeutics retweeted
$SNY, @scribetx line up 2nd potential billion-dollar deal, this one aimed initially at sickle cell disease
bizjournals.com/sanfrancisco… via @SFBusinessTimes
Scribe Therapeutics retweeted
The CRISPR enzyme CasX comes with key potential advantages, including that it’s free from the intellectual property fight surrounding Cas9, the original DNA-cutting tool. trib.al/c037CRt
Scribe Therapeutics retweeted
Sanofi licenses CRISPR enzyme in bid to develop safer, simpler sickle cell cure
statnews.com/2023/07/17/sick…
Scribe Therapeutics retweeted
Sanofi is taking another dip in Scribe's CRISPR pool, inking a new in vivo gene editing partnership worth more than $1.2 billion. fiercebiotech.com/biotech/sa…
Scribe Therapeutics retweeted
Kudos to @Sanofi & @scribetx Therapeutics on expanding their collaboration! Their partnership combines Scribe's #CRISPRbyDesign & Sanofi's non-viral delivery prowess to target sickle cell disease. A leap in #CRISPR gene editing for global health.
businesswire.com/news/home/2…
Scribe Therapeutics retweeted
It was a pleasure to join the @technology show on @BloombergTV. Check it out below!👇
Thanks to @CarolineHydeTV for an insightful conversation on the potential of @scribetx’s #CRISPRbyDesign approach and X-Editing technology to treat disease at scale
bloomberg.com/news/videos/20…
Scribe Therapeutics retweeted
Congrats to @BenjaminLOakes and @scribetx on the launch of a promising collaboration with Prevail Therapeutics and @EliLillyandCo.
Scribe's #CRISPRbyDesign approach is poised to impact how we treat not only neurological and neuromuscular conditions, but broader disease at scale.
We’re proud to announce a strategic collaboration with Prevail Therapeutics, a subsidiary of @EliLillyandCo, that will leverage Scribe's #CRISPR X-Editing (XE) technologies to accelerate novel in vivo therapies for neurological and neuromuscular diseases. businesswire.com/news/home/2…
Scribe Therapeutics retweeted
.@scribetx will partner with @EliLillyandCo subsidiary Prevail Therapeutics to develop in vivo #CRISPR based therapies for neurological and #neuromuscular diseases, through an up-to-$1.5 billion collaboration. Learn more: ow.ly/5c7T50Op2Xh
